Erratum: Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1) (Eur. J. Pharmacol. (2013) 707:1-3 (140-146) (DOI: 10.1016/j.ejphar.2013.03.019));Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1)

European Journal of Pharmacology

Volumn 707, Issue 1-3, 2013, Pages 140-146

  Voss, Marc D ^a   Zoller, Gerhard ^a   Matter, Hans ^a   Herling, Andreas W ^a   Biemer Daub, Gabriele ^a   Pfenninger, Anja ^a   Haag Diergarten, Silke ^a   Keil, Stefanie ^a   Kohlmann, Markus ^a   Schmidts, Hans Ludwig ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Fatty acid desaturation; Hexahydro pyrrolopyrrole; Inhibitor; SCD1; Stearoyl CoA desaturase; Zucker diabetic fatty rat

Indexed keywords

ACYL COENZYME A DESATURASE 1; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; ENZYME INHIBITOR; GLUCOSE; PYRROLE DERIVATIVE; SAR 707; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; DERMATITIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESEARCH; DYSLIPIDEMIA; ENZYME INHIBITION; EYELID; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACOLOGICAL PARAMETERS; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; SERUM DESATURATION INDEX; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ZUCKER DIABETIC FATTY RAT;

EID: 84877580628     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.024     Document Type: Erratum

References (36)

1. Abreo, M., Harvey, D.F., Kondratenko, M., Li, W., Kamboj, R., Kodumuru, R., Winther, M.D., Gschwend, H.W. Chakka, N., Liu. S., Sviridov. S., Sun, S., 2005a. PCT Int. Appl. WO2005011654.
2. Abreo, M., Chafeev, M., Chakka, N., Chowdhury, S., Fu, J., Gschwend, H.W., Sun, S., Sun, S., Sviridov, S.,Tu, C., Winther, M.D., Zhang, Z., 2005b. Pyridazine Derivatives and Their Use at Therapeutic Agents. PCT Int. Appl. WO2005011655.
3. P. Artursson, K. Palma, and K. Luthman Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv. Drug Deliv. Rev. 46 2001 27 43
4. K.A. Atkinson, E.E. Beretta, J.A. Brown, M. Castrodad, Y. Chen, J.M. Cosgrove, P. Du, J. Litchfield, M. Michael Makowski, K. Martin, T.J. McLellan, C. Neagu, D.A. Perry, D.W. Piotrowski, C.M. Steppan, and R. Trilles N-Benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors Bioorg. Med. Chem. Lett. 21 2011 1621 1625
5. E. Binczek, B. Jenke1, B. Holz1, R.H. Guenter, M. Mario Thevis, and W. Stoffel Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation Biol. Chem. 388 2007 405 418
6. P. Cohen, M. Miyazaki, N.D. Socci, A. Hagge-Greenberg, W. Liedtke, A.A. Soukas, R. Sharma, L.C. Hudgins, J.M. Ntambi, and J.M. Friedman Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss Science 297 2002 240 243
7. H.G. Enoch, A. Catala, and P. Strittmatter Mechanism of rat liver microsomal stearoyl-CoA desaturase: studies of the substrate specificity, enzyme-substrate interactions and the function of lipid J. Biol. Chem. 251 1976 5095 5103
8. Fu, J., Kodumuru, V., Sun, S., Winther, M., Fine, R.M., Harvey, D.F., Klebansky, B., Gray-Keller, M.P., Gschwend, H.W., Li, W., 2005. Preparation of Nicotinamide Derivatives and Their Use as Therapeutic Agents for Treating Stearoyl-CoA Desaturase-Mediated Diseases. U.S. Pat. Appl. US20050119251.
9. Gschwend, H.W., Kodumuru, V., Liu, S., Kamboj, R. PCT Int. Appl WO2005011653A2.
10. R.A. Igal Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer Carcinogenesis 31 2010 1509 1515
11. E. Isabel, D.A. Powell, W.C. Black, C.-C. Chan, S. Crane, R. Gordon, J. Guay, S. Guiral, Z. Huang, J. Robichaud, K. Skorey, P. Tawa, L. Xu, L. Zhang, and R. Oballa Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors Bioorg. Med. Chem. Lett. 21 2011 479 483
12. M. Issandou, A. Bouillot, J.M. Brusq, M.C. Forest, D. Grillot, R. Guillard, S. Martin, C. Michiels, T. Sulpice, and A. Daugan Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models Eur. J. Pharmacol. 618 2009 28 36
13. G. Jiang, Z. Li, F. Liu, K. Ellsworth, Q. Dallas-Yang, M. Wu, J. Ronan, C. Esau, C. Murphy, D. Szalkowski, R. Bergeron, T. Doebber, and B.B. Zhang Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1 J. Clin. Invest. 115 2005 1030 1038
14. S. Keil, M. Müller, G. Zoller, G. Haschke, K. Schroeter, M. Glien, S. Ruf, I. Focken, A.W. Herling, and D. Schmoll Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation J. Med. Chem. 53 2010 8679 8687
15. C.S. Li, L. Belair, J. Guay, R. Murgasva, W. Sturkenboom, Y.K. Ramtohul, L. Zhang, and Z. Huang Thiazole analog as stearoyl-CoA desaturase 1 inhibitor Bioorg. Med. Chem. Lett. 19 2009 5214 5217
16. Li, C.S., Ramtohul, Y.K., Huang, Z., Lachance, N., 2006. Preparation of Azacyclohexane Derivatives as Inhibitors of Stearoyl-Coenzyme A Delta-9 Desaturase. Intl. Pat. Appl. WO2006130986.
17. G. Liu, J.K. Lynch, J. Freeman, B. Liu, Z. Xin, H. Zhao, M.D. Serby, P.R. Kym, T.S. Suhar, H.T. Smith, N. Cao, R. Yang, R.S. Janis, J.A. Krauser, S.P. Cepa, D.W.A. Beno, H. Sham, C.A. Collins, T.K. Surowy, and H.S. Camp Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors J. Med.Chem. 50 2007 3086 3100
18. C. McMartin, and R.S. Bohacek QXP: powerful, rapid computer algorithms for structure-based drug design J. Comp.-Aided Mol. Des. 11 1997 333 344
19. C.W. Miller, and J.M. Ntambi Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression Proc. Nat. Acad. Sci. USA 93 1996 9443 9448
20. M. Miyazaki, M.T. Flowers, H. Sampath, K. Chu, C. Otzelberger, X. Liu, and J.M. Ntambi Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis Cell Metab. 6 2007 4 96
21. J.M. Ntambi Dietary regulation of stearoyl-CoA desaturase 1 gene expression in mouse liver J. Biol. Chem 267 1992 10925 10930
22. J.M. Ntambi The regulation of stearoyl-CoA desaturase (SCD) Prog. Lipid Res. 34 1995 139 150
23. J.M. Ntambi, M. Miyazaki, J.P. Stoehr, H. Lan, C.M. Kendziorski, B.S. Yandell, Y. Song, P. Cohen, J.M. Friedman, and A.D. Attie Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity Proc Nat. Acad. Sci. USA 17 2002 11482 11486
24. R.M. Oballa, L. Belair, W.C. Black, K. Bleasby, C.C. Chan, C. Desroches, X. Du, R. Gordon, J. Guay, S. Guiral, M.J. Hafey, E. Hamelin, Z. Huang, B. Kennedy, N. Lachance, F. Landry, C.S. Li, J. Mancini, D. Normandin, A. Pocai, D.A. Powell, Y.K. Ramtohul, K. Skorey, D. Sørensen, W. Sturkenboom, A. Styhler, D.M. Waddleton, H. Wang, S. Wong, L. Xu, and L. Zhang Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia J. Med. Chem. 28 2011 5082 5096
25. Y.K. Ramtohul, C. Black, C.C. Chan, S. Crane, J. Guay, S. Guiral, Z. Huang, R. Oballa, L.J. Xu, L. Zhang, and C.S. Li SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors Bioorg. Med. Chem. Lett. 20 2010 1593 1597
26. D.A. Ratkovsky, and T.J. Reedy Choosing near-linear parameters in the four parameters logistic model radioligands and related assays Biometrics 42 1986 575 582
27. S. Smyth, and A. Heron Diabetes and obesity: the twin epidemics Nat. Med. 12 2006 75 80
28. A.A. Toye, M.E. Dumas, C. Blancher, A.R. Rothwell, J.F. Fearnside, S.P. Wilder, M.T. Bihoreau, O. Cloarec, I. Azzouzi, S. Young, R.H. Barton, E. Holmes, M.I. McCarthy, R. Tatoud, J.K. Nicholson, J. Scott, and D Gauguier Subtle metabolic and liver gene transcriptional changes underlie diet-induced fatty liver susceptibility in insulin-resistant mice Diabetologia 50 2007 1867 1879
29. Y. Uto, Y. Kiyotsuka, Y. Ueno, Y. Miyazawa, H. Kurata, T. Ogata, T. Deguchi, M. Yamada, N. Watanabe, M. Konishi, N. Kurikawa, T. Takagi e Satoko, W. Wakimoto, K. Kono, and J Ohsumi Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: identification of 10-{6-[5-(pyridin-3-ylmethyl)- 1,3,4-oxadiazol-2-yl]-pyridazin-3-yl}-5 (trifluoro methyl)-3,4- dihydrospiro[chromene-2,40-piperidine] Bioorg. Med. Chem. Lett. 20 2010 746 754
30. Y. Uto, T. Ogata, Y. Kiyotsuka, Y. Ueno, Y. Miyazawa, H. Kurata, T. Deguchi, N. Watanabe, M. Konishi, R. Okuyama, N. Kurikawa, T. Takagi, S. Wakimoto, and J. Ohsumi Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3- carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats Bioorg. Med. Chem. Lett. 20 2010 341 345
31. M.D. Voss, A. Beha, N. Tennagels, G. Tschank, A.W. Herling, M. Quint, M. Gerl, C. Metz-Weidmann, G. Haun, and M. Korn Gene expression profiling in skeletal muscle of Zucker diabetic fatty rats: implications for a role of stearoyl-CoA desaturase 1 in insulin resistance Diabetologia 48 2005 2622 2630
32. E. Warensjö, E. Ingelsson, P. Lundmark, L. Lannfelt, A.C. Syvänen, B. Vessby, and U. Risérus Polymorphisms in the SCD1 gene: associations with body fat distribution and insulin sensitivity Obesity (Silver Spring) 15 2007 1732 1740
33. Z. Xin, H. Zhao, M.D. Serby, B. Liu, M. Liu, B.G. Szczepankiewicz, L.T.J. Nelson, H.T. Smith, T.S. Suhar, R.S. Janis, N. Cao, H.S. Camp, C.A. Collins, H.L. Sham, T.K. Surowy, and G. Liu Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors Bioorg. Med. Chem. Lett. 18 2008 4298 4302
34. Y. Zheng, K.J. Eilertsen, L. Ge, L. Zhang, J.P. Sundberg, S.M. Prouty, K.S. Stenn, and S. Parimoo Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse Nat. Genet. 23 1999 268 270
35. Zoller, G., Voss, M.D., Keil, S., Herling, A., Matter, H., 2008. Preparation of Hexahydropyrrolo[3,4- c] Pyrroles as Stearoyl CoA Desaturase Inhibitors. PCT Int. Appl. WO2008135141.
36. Zoller, G., Voss, M.D., Matter, H., Herling, A., 2010. Preparation of 2-Heteroarylpyrrolo[3,4-c]Pyrroles as Stearoyl CoA Desaturase (SCD) Inhibitors. PCT Int. Appl. WO2010/028761.